MX9205240A - Composicion y metodo para tratar hepatitis c. - Google Patents

Composicion y metodo para tratar hepatitis c.

Info

Publication number
MX9205240A
MX9205240A MX9205240A MX9205240A MX9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A MX 9205240 A MX9205240 A MX 9205240A
Authority
MX
Mexico
Prior art keywords
composition
treating hepatitis
thymosins
alone
compositions
Prior art date
Application number
MX9205240A
Other languages
English (en)
Spanish (es)
Inventor
Paul Chretien
Milton Mutchnick
Original Assignee
Paul Chretien
Milton Mutchnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Chretien, Milton Mutchnick filed Critical Paul Chretien
Publication of MX9205240A publication Critical patent/MX9205240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
MX9205240A 1991-09-13 1992-09-14 Composicion y metodo para tratar hepatitis c. MX9205240A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
MX9205240A true MX9205240A (es) 1993-07-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205240A MX9205240A (es) 1991-09-13 1992-09-14 Composicion y metodo para tratar hepatitis c.

Country Status (23)

Country Link
US (3) US6001799A (OSRAM)
EP (1) EP0603305B1 (OSRAM)
JP (1) JP3228512B2 (OSRAM)
KR (1) KR100254082B1 (OSRAM)
AT (1) ATE152914T1 (OSRAM)
AU (1) AU667327B2 (OSRAM)
CA (1) CA2119006C (OSRAM)
CZ (1) CZ286827B6 (OSRAM)
DE (1) DE69219782T2 (OSRAM)
DK (1) DK0603305T3 (OSRAM)
ES (1) ES2103966T3 (OSRAM)
FI (1) FI107879B (OSRAM)
GR (1) GR3024025T3 (OSRAM)
HK (1) HK1021687A1 (OSRAM)
HU (1) HU221006B1 (OSRAM)
MX (1) MX9205240A (OSRAM)
NO (1) NO941310D0 (OSRAM)
RO (1) RO111991B1 (OSRAM)
RU (1) RU2104010C1 (OSRAM)
SG (1) SG64897A1 (OSRAM)
TW (1) TW224053B (OSRAM)
WO (1) WO1993005806A1 (OSRAM)
ZA (1) ZA926964B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (OSRAM) * 1991-09-13 1994-05-21 Paul B Chretien
EP0728010A4 (en) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals METHOD FOR TREATING HEPATITIS B CARRIERS WITH A MINOR DISEASE
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (OSRAM) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
EP0731710B1 (en) * 1993-11-05 2003-05-14 Alpha 1 Biomedicals, Inc. Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011749A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
PL371683A1 (en) * 2001-10-05 2005-06-27 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
PL370453A1 (en) * 2001-10-26 2005-05-30 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
EP2799442A1 (en) 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
CN100342907C (zh) * 2003-03-28 2007-10-17 希克龙制药公司 胸腺素α1在制备用于治疗或预防哺乳动物中曲霉菌感染的药物组合物中的应用
EP1613340B1 (en) 2003-03-28 2010-05-12 SciClone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
FI2604620T4 (fi) 2003-05-30 2024-09-11 Gilead Pharmasset Llc Modifioituja fluorinoituja nukleosidianalogeja
ATE478886T1 (de) * 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
KR101380360B1 (ko) * 2006-05-02 2014-04-09 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010042697A1 (en) * 2008-10-08 2010-04-15 University Of Miami Regulation of lymphocytes and uses therefor
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
ES2537785T3 (es) 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (OSRAM) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
DE69219782D1 (de) 1997-06-19
SG64897A1 (en) 1999-05-25
WO1993005806A1 (en) 1993-04-01
AU667327B2 (en) 1996-03-21
HU9400758D0 (en) 1994-06-28
JPH06510998A (ja) 1994-12-08
ES2103966T3 (es) 1997-10-01
RU94022480A (ru) 1996-07-20
US20070218033A1 (en) 2007-09-20
FI941133L (fi) 1994-03-10
CZ286827B6 (cs) 2000-07-12
NO941310L (no) 1994-04-12
CZ55194A3 (en) 1994-10-19
FI941133A0 (fi) 1994-03-10
EP0603305B1 (en) 1997-05-14
HU221006B1 (hu) 2002-07-29
KR100254082B1 (ko) 2000-09-01
NO941310D0 (no) 1994-04-12
JP3228512B2 (ja) 2001-11-12
FI107879B (fi) 2001-10-31
DE69219782T2 (de) 1997-10-09
AU2644792A (en) 1993-04-27
DK0603305T3 (da) 1997-09-01
ZA926964B (en) 1993-04-26
RO111991B1 (ro) 1997-04-30
US6001799A (en) 1999-12-14
RU2104010C1 (ru) 1998-02-10
HK1021687A1 (en) 2000-06-23
GR3024025T3 (en) 1997-10-31
CA2119006A1 (en) 1993-04-01
ATE152914T1 (de) 1997-05-15
EP0603305A1 (en) 1994-06-29
TW224053B (OSRAM) 1994-05-21
HUT75166A (en) 1997-04-28
US5849696A (en) 1998-12-15
CA2119006C (en) 2005-08-23

Similar Documents

Publication Publication Date Title
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
AT346468B (de) Ein- oder mehrteiliges, insbesondere keramisches implantat
MX9304209A (es) Composicion y metodo de tratamiento de hepatitis b.
BR9105737A (pt) Processo para reduzir a contaminacao de um produto de amplificacao,conjunto para uso em um tipo de procedimento de amplificacao e processo para amplificar uma sequencia de amplificacao de uma sequencia-alvo
ATE185483T1 (de) Antivirale nucleosidkombination
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
DK282585D0 (da) Synergistiske blandinger af interferoner og tumor-nekrose-faktor
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
DK486588A (da) Konjungater af cytokininer med immunglobuliner
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
DK214889A (da) Ikke-vandigt, ikke-ionisk, kraftigt virkende vaskemiddel med forbedret stabilitet under anvendelse af mikrokugler og/eller vicinal-hydroxyforbindelser
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
TR200002323T2 (tr) Hepatit virüs enfeksiyonlarının tedavi edilmesi için N-ikameli-1,5-dideoksi 1,5-imino-D-glusitol bileşiklerinin kullanımı
GT198301619A (es) Interferon inmune humano homogeneo y procedimiento para el mismo.
TR199801289T2 (en) Terap�tik bile�ikler.
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES2036526T3 (es) Composiciones de interferon.
ES2177531T3 (es) Receptor de lipoproteinas de baja densidad (ldl), su produccion y su utilizacion.
ATE71840T1 (de) Virushemmende nukleosidmischung.
FI941552A0 (fi) Gamma-INF:n käyttö infektioiden hoitoon siirrännäisten saajilla
MX9302578A (es) Agentes antivirales.
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections

Legal Events

Date Code Title Description
FG Grant or registration
MK Ceased due to expiration of term